Handelsbanken Fonder AB Acquires 450,000 Shares of Cellebrite DI Ltd. $CLBT

Handelsbanken Fonder AB raised its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,900,000 shares of the company’s stock after buying an additional 450,000 shares during the period. Handelsbanken Fonder AB’s holdings in Cellebrite DI were worth $53,737,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of CLBT. Redmond Asset Management LLC raised its position in shares of Cellebrite DI by 1.6% in the third quarter. Redmond Asset Management LLC now owns 192,715 shares of the company’s stock valued at $3,571,000 after purchasing an additional 3,078 shares during the period. TD Asset Management Inc grew its stake in Cellebrite DI by 52.8% in the 3rd quarter. TD Asset Management Inc now owns 324,241 shares of the company’s stock valued at $6,008,000 after buying an additional 112,005 shares during the last quarter. Granite Investment Partners LLC acquired a new position in Cellebrite DI in the 3rd quarter valued at about $11,406,000. Telemark Asset Management LLC raised its holdings in Cellebrite DI by 20.0% in the 3rd quarter. Telemark Asset Management LLC now owns 600,000 shares of the company’s stock valued at $11,118,000 after acquiring an additional 100,000 shares during the period. Finally, King Luther Capital Management Corp acquired a new stake in Cellebrite DI during the third quarter worth approximately $5,582,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Lake Street Capital upped their target price on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Finally, Bank of America boosted their target price on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $13.34 on Friday. The firm has a market cap of $3.19 billion, a PE ratio of 43.03, a price-to-earnings-growth ratio of 2.11 and a beta of 1.28. The stock’s fifty day moving average price is $16.05 and its two-hundred day moving average price is $16.96. Cellebrite DI Ltd. has a one year low of $11.76 and a one year high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. During the same period in the prior year, the firm posted $0.10 EPS. Cellebrite DI’s quarterly revenue was up 28.8% on a year-over-year basis. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.